Phase 3 Clinical Trials With Primary Completion Dates in August 2017

This is a list of Phase 3 trials with primary completion dates in August 2017 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

Symbol Company Primary Completion Date Phase NCT ID Title
ADMS Adamas Pharmaceuticals, Inc. 2017-08-01 Phase 3 NCT02202551 Open-Label Safety Study of ADS-5102 in PD Patients With LID
ARDX Ardelyx, Inc. 2017-08-01 Phase 3 NCT02686138 A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
BIVV Bioverativ Inc. 2017-08-01 Phase 3 NCT01454739 Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A
BIVV Bioverativ Inc. 2017-08-01 Phase 3 NCT01425723 Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B
CEMP Cempra, Inc. 2017-08-01 Phase 3 NCT02210325 Efficacy and Safety Study of Oral Solithromycin Compared to Intramuscular Ceftriaxone Plus Oral Azithromycin in the Treatment of Patients With Gonorrhea
CTIC CTI BioPharma Corp. 2017-08-01 Phase 3 NCT01321541 Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
DBVT DBV Technologies S.A. 2017-08-01 Phase 3 NCT02636699 Efficacy and Safety of Viaskin Peanut in Children With Immunoglobulin E (IgE)-Mediated Peanut Allergy
DRRX DURECT Corporation 2017-08-01 Phase 3 NCT02574520 Trial of Extended Release Bupivacaine for Pain Relief After Surgery
EGLT Egalet Corporation 2017-08-01 Phase 3 NCT02716857 Efficacy and Safety of Egalet-002 in Patients With Moderate-to-Severe Chronic Low Back Pain
ENDP Endo International plc 2017-08-01 Phase 3 NCT00356213 Comparison of Laparoscopic Sleeve Gastrectomy and Roux-Y-gastric Bypass in the Treatment of Morbid Obesity
KALA Kala Pharmaceuticals, Inc. 2017-08-01 Phase 3 NCT02819284 Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease
KALA Kala Pharmaceuticals, Inc. 2017-08-01 Phase 3 NCT02813265 Safety and Efficacy of KPI-12 in Subjects With Dry Eye Disease
LIVN LivaNova PLC 2017-08-01 Phase 3 NCT03014180 Clinical Evaluation of LEft VEntricular Auto Threshold Alogrithm (LEVEA)
MTFB Motif Bio plc 2017-08-01 Phase 3 NCT02607618 Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-2
NBRV Nabriva Therapeutics plc 2017-08-01 Phase 3 NCT02813694 Study to Compare Lefamulin to Moxifloxacin for the Treatment of Adults With Pneumonia
NDRM NeuroDerm Ltd. 2017-08-01 Phase 3 NCT02782481 A Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor Fluctuations
NURO NeuroMetrix, Inc. 2017-08-01 Phase 3 NCT02809846 Quell Opioid Reduction and Pain Relief in Patients With Cancer
ORPN Bioblast Pharma Ltd. 2017-08-01 Phase 3 NCT02328482 Continuation Protocol to Protocol BBCO-001
RARE Ultragenyx Pharmaceutical Inc. 2017-08-01 Phase 3 NCT02537431 Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)
VSAR Versartis, Inc. 2017-08-01 Phase 3 NCT02339090 Versartis Long-Acting Growth Hormone in Children Compared to Daily rhGH
ZGNX Zogenix, Inc. 2017-08-01 Phase 3 NCT02926898 A Two-Part Study to Investigate the Dose-Ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children ≥2 Years Old and Young Adults With Dravet Syndrome